SOURCE-LINKED STUDY SUMMARY
Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.
Full paper summarizedQuality not appraised
- What was studied
- A double-blind trial examined cardiac effects of blocking the myostatin-activin receptor pathway.
- Who / model studied
- 68 healthy older adults aged 60 to 86; not all completed treatment.
- Studied dose & schedule
- Intravenous bimagrumab 10 mg/kg or placebo every 4 weeks over 24 weeks.
- What the study found
- No significant between-group differences in left-ventricular mass index or ejection fraction emerged. Lean mass increased and fat mass decreased. Muscle spasms occurred in 57.1% versus 6.1%.
- Limitations & context
- Small, single-site study with substantial attrition. The findings do not establish long-term cardiovascular safety or safety in people with heart disease.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1210/clinem/dgag091